Skip to main content

Table 3 Heart failure therapy and response to heart failure treatment

From: Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy

  Overall (n = 92) Early (n = 49) Late (n = 43) p-value
Heart failure treatment initiation 0.258
 Initiated 63 (68) 36 (73) 27 (63)
 Adding to previous therapy 5 (5) 1 (2) 4 (9)
 LVEF > 45% and no cardiac complaints 24 (26) 12 (24) 12 (28)
Number of HF drugs 0.162
 1 32 (47) 20 (54) 12 (39)
 2 28 (41) 15 (41) 13 (42)
 3 8 (12) 2 (5) 6 (19)
ACE inhibitors / ARB 0.538
 n 61 (90) 34 (92) 27 (87)
 % of target dose 25 [16.7–50] 25 [16.7–50] 25 [25–41.5]
Beta-blockers 0.183
 n 39 (57) 18 (49) 21 (68)
 % of target dose 25 [12.5–50] 18.75 [12.5–25] 25 [12.5–50]
MRA  
 n 6 (9) 2 (5) 4 (13)
 % of target dose 37.5 [25–50] 37.5 [25–50] 37.5 [25–50]
Side effects  
 Hypotension 18 (26) 10 (27) 8 (26)
 Renal dysfunction 3 (4) 1 (3) 2 (6)
 Other 6 (9) 3 (8) 3 (10)
Duration of HF treatment (months) 16.8 [4.8–29.8] 14.6 [3.4–28.0] 25.3 [10.1–35.2] 0.038*
Response to HF therapy
  Overall
(n = 50)
(partial) recovery (n = 26) No recovery (n = 24) p-value
Response to HF therapy 0.011*
 Early 26 (51) 18 (69) 8 (33)
 Late 24 (49) 8 (31) 16 (67)
Number of HF drugs 0.669
 1 22 (44) 12 (46) 10 (42)
 2 20 (40) 9 (35) 11 (46)
 3 8 (16) 5 (19) 3 (12)
ACE inhibitors / ARB 0.316
 n 46 (92) 23 (88) 23 (96)
 % of target dose 25 [16.7–50] 25 [12.5–50] 25 [25–50]
Beta-blockers 0.713
 n 29 (59) 16 (62) 14 (58)
 % of target dose 25 [12.5–50] 25 [12.5–50] 37.5 [12.5–50]
Duration of HF treatment (months) 21.9 [13.5–30.9] 22.3 [13.5–30.9] 25.9 [13.3–36.6] 0.547
  1. Target doses are expressed as percentage of target dose according to the ESC Guideline on Heart Failure [12]. Categorical variables are expressed as n (%) and continuous variables as mean (standard deviation) or median [interquartile range]. LVEF Left ventricular ejection fraction, HF Heart failure, ACE Angiotensin converting enzyme, ARB Angiotensin II receptor blockers, MRA Mineralocorticoid receptor antagonist; * p-value < 0.05